"V体育2025版" Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The VSports app下载. gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. V体育官网.

Review

ASAH1-Related Disorders

In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993.
.
Affiliations
Free Books & Documents
Review

ASAH1-Related Disorders

David A Dyment et al.
Free Books & Documents

Excerpt

Clinical characteristics: The spectrum of ASAH1-related disorders ranges from Farber disease (FD) to spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME). VSports手机版.

Classic FD is characterized by onset in the first weeks of life of painful, progressive deformity of the major joints; palpable subcutaneous nodules of joints and mechanical pressure points; and a hoarse cry resulting from granulomas of the larynx and epiglottis. Life expectancy is usually less than two years V体育安卓版. In the other less common types of FD, onset, severity, and primary manifestations vary.

  • SMA-PME is characterized by early-childhood-onset progressive lower motor neuron disease manifest typically between ages three and seven years as proximal lower-extremity weakness, followed by progressive myoclonic and atonic seizures, tremulousness/tremor, and sensorineural hearing loss. Myoclonic epilepsy typically begins in late childhood after the onset of weakness and can include jerking of the upper limbs, action myoclonus, myoclonic status, and eyelid myoclonus. Other findings include generalized tremor, and cognitive decline. The time from disease onset to death from respiratory complications is usually five to 15 years V体育ios版.

  • Diagnosis/testing: The diagnosis of an ASAH1-related disorder is established in a proband with suggestive clinical findings by identification of biallelic pathogenic variants in ASAH1 and/or decreased activity of the enzyme acid ceramidase in peripheral blood leukocytes or cultured skin fibroblasts. VSports最新版本.

    Management: Treatment of manifestations is symptomatic and multidisciplinary V体育平台登录. .

    For FD: Management may include gastrostomy tube placement, surgical removal of oral and airway granulomas, and treatment of seizures as per standard practice VSports注册入口. Hematopoietic stem cell transplantation may be an option in affected individuals who do not have significant neurologic involvement.

  • For SMA-PME: Management may include standard treatment for hearing loss, scoliosis, seizures, and tremor V体育官网入口. Weakness can be mitigated with the use of orthotics, wheelchairs, or other assistive devices.

  • Surveillance:

    1. For FD: At each visit assess growth with emphasis on feeding and nutritional status; airway, joint mobility, and developmental milestones.

    2. For SMA-PME: At each visit monitor growth with emphasis on feeding and nutritional status, pulmonary function, back for evidence of scoliosis, strength, seizure control, functional capacity (e. g. , mobility, communication); assess hearing annually V体育2025版.

    Genetic counseling: ASAH1-related disorders are inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Sibs with the same two pathogenic variants would be expected to have the same (or very similar) phenotype. Once the ASAH1 pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives and prenatal and preimplantation genetic testing are possible.

    PubMed Disclaimer

    References

      1. Abul-Haj SK, Martz DG, Douglas WF, Geppert LJ. Farber's disease. Report of a case with observations on its histogenesis and notes on the nature of the stored material. J Pediatr. 1962;61:221–32. - PubMed
      1. Al Jasmi F. A novel mutation in an atypical presentation of the rare infantile Farber disease. Brain Dev. 2012;34:533–5. - PubMed
      1. Alayoubi AM, Wang JC, Au BC, Carpentier S, Garcia V, Dworski S, El-Ghamrasni S, Kirouac KN, Exertier MJ, Xiong ZJ, Privé GG, Simonaro CM, Casas J, Fabrias G, Schuchman EH, Turner PV, Hakem R, Levade T, Medin JA. Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Mol Med. 2013;5:827–42. - PMC - PubMed
      1. Alves MQ, Le Trionnaire E, Ribeiro I, Carpentier S, Harzer K, Levade T, Ribeiro MG. Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene. Mol Genet Metab. 2013;109:276–81. - "V体育官网" PubMed
      1. Bär J, Linke T, Ferlinz K, Neumann U, Schuchman EH, Sandhoff K. Molecular analysis of acid ceramidase deficiency in patients with Farber disease. Hum Mutat. 2001;17:199–209. - PubMed

    "V体育官网入口" Publication types

    LinkOut - more resources (V体育2025版)